
Polypharmacy in Aging HIV Patients and Evaluating New Antiretroviral Agents
An aging HIV population brings mounting medication lists, and pharmacists must streamline regimens while critically judging whether each new agent offers real innovation or only incremental change.
Episodes in this series

In "Polypharmacy in Aging HIV Patients and Evaluating New Antiretroviral Agents," our experts address two practical challenges: medication overload in aging patients and appraising new agents.
Dr. Burkhart explains that people with HIV are living much longer and accumulating comorbidities such as diabetes, hypertension, and hyperlipidemia. Each condition adds medications on top of antiretroviral therapy, which can be exhausting for patients. He describes one patient at his site taking more than 20 medications daily. His pharmacy offers blister packaging to help patients stay on track. Cognitive changes with age can leave patients unsure whether they took a dose, took the wrong medication, or skipped it entirely.
Dr. Madison adds that streamlining requires a review of every medication. Post-hospitalization is a key moment, since patients are often discharged with new prescriptions. Specialists may also add therapies the HIV team does not know about. She recommends a traditional brown-bag review. The pharmacist asks whether the patient still takes each drug, how they take it, and whether it still works.
Dr. Astle then describes how he evaluates a newly approved agent. He starts with the pivotal studies, including how they were structured and whether the enrolled patients resemble his own population. Many newer agents target highly treatment-experienced patients or switching scenarios, so their immediate impact may be limited. He next looks at outcomes beyond noninferior viral suppression. Tolerability, patient response, and practical dosing all matter. He asks whether the agent can realistically be built into practice. Finally, he weighs access. Insurance challenges, procurement hurdles, and supply chain issues may create new barriers rather than remove them.
Dr. Madison agrees wholeheartedly. She reflects that early in her HIV career, the goal was simply keeping people alive. Today the focus has shifted from the quantity of years to the quality of those years. Many newer studies now measure that quality-of-life dimension directly.
Our next episode, "Personalizing HIV Regimens: Patient Preferences, Bone, Lipids, and Comorbidities," turns to patient-reported factors and comorbidities that shape regimen selection.
Funding supported by Gilead. Content independently developed by Pharmacy Times.
Related to this article








